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ScienceDirectIncretin peptides (glucagon-like peptide-1 (GLP-1) and
glucose-dependent insulinotropic polypeptide (GIP)) are
secreted from enteroendocrine cells in the intestinal epithelium,
and help to coordinate metabolic responses to food ingestion.
A number of molecular mechanisms have recently been
defined that underlie carbohydrate, lipid and protein sensing in
gut endocrine cells. Knockout mice lacking sodium glucose
tranporter-1 (SGLT-1) or the short chain fatty acid sensing
receptor FFAR2 (GPR43), for example, have highlighted the
importance of these molecules in incretin secretion. This review
outlines our current understanding of sensory pathways in
incretin secreting cells and highlights the therapeutic potential
of targeting them for the development of novel therapies for
obesity and diabetes.
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Introduction
The gastrointestinal (GI) tract, in addition to digesting
food and absorbing the available nutrients, releases hor-
mones with important physiological roles in regulating
plasma glucose levels, gut motility and satiety. Amongst
these, glucagon-like peptide-1 (GLP-1) and glucose-de-
pendent insulinotropic polypeptide (GIP) are known as
incretins, based on their ability to enhance glucose-stimu-
lated insulin secretion. The possibility of stimulating the
release of endogenous incretins as a therapeutic strategy for
the treatment of type 2 diabetes (T2DM) and obesity has
led to heightened interest in the physiology of enteroen-
docrine cells and the gut-brain-pancreatic axis. This review
 
Open access under CC BY-NC-ND license.Current Opinion in Pharmacology 2013, 13:922–927 will focus on our current understanding of the enteroendo-
crine cell populations known as K-cells and L-cells, which
primarily secrete GIP and GLP-1, respectively.
Enteroendocrine cells have historically been difficult to
study as they are found scattered within the intestinal
epithelium, but recent advances in labelling specific cell
populations in transgenic mice with fluorescent reporters
have enabled live cell identification and purification. As a
consequence, there are increasing numbers of published
studies analysing the molecular events underlying stimulus
secretion coupling in enteroendocrine cell types. An unex-
pected outcome of these investigations has been the
observation that enteroendocrine cells are more plurihor-
monal than previously thought. Although L-cells have long
been known to produce peptideYY (PYY) in addition to the
products of proglucagon processing (GLP-1, GLP-2 and
oxyntomodulin), it was surprising to find that most K-cells
and L-cells also produce cholecystokinin (CCK) [1,2].
Many mechanisms described here might also therefore
play a role in the secretion of other enteroendocrine
hormones, although the relative contributions of different
signalling pathways likely differ between cells and along
the length of the GI tract. Thus, whereas GIP secreting K-
cells are predominantly located in the duodenum and are
exposed to nutrients soon after food ingestion, GLP-1 is
also produced more distally where its secretion may be
influenced by slowly digested macronutrients and products
of bacterial fermentation (Figure 1).
L-cells and K-cells, like many of the enteroendocrine
family, consist of an apical pole with microvilli facing
the gut lumen and a broader base where peptides are
released, and it is believed that peptide secretion is a
result of direct sensing of nutrients in the lumen [3].
Recent work has begun to elucidate the mechanisms
underlying nutrient sensing and peptide release, and in
vitro studies suggest that L-cells are electrically active,
exhibiting action potentials and calcium transients in
response to glucose [4]. Whilst minor differences in
glucose sensing by K-cells have been described [5], many
molecular mechanisms described below are active in GIP
and GLP-1 secreting cells and are likely also to be
involved in the release of other enteroendocrine hor-
mones. However, to what extent the different identified
sensory pathways contribute to nutrient detection in vivo
remains to be fully established.
Nutrient signalling
Carbohydrate sensing
Glucose is a robust stimulant of incretin release and
several pathways of carbohydrate sensing have beenwww.sciencedirect.com
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Model of the molecular mechanisms involved in the secretion of incretin peptides from enteroendocrine cells. Stimulation of nutrient and non-nutrient
pathways ultimately leads to an increase in intracellular calcium via G protein coupled pathways or membrane depolarisation, facilitating the release of
incretin peptides. The effect of incretin peptides on orchestrating the physiological response to nutrient intake, such as potentiating glucose-
dependent insulin secretion, is facilitated through peptide uptake into blood vessels of the portal vein and/or through direct activation of neighbouring
neuronal afferents.proposed. In the upper small intestine, there is good
evidence that GLP-1 and GIP release are triggered by
Na+ coupled glucose uptake mediated by the brush
border sodium glucose cotransporter (SGLT1). Small
transporter-associated currents appear sufficient to drive
membrane depolarisation, in turn triggering electrical
activity, voltage-gated calcium entry and peptide release
[6]. This idea is supported by the demonstration that
glucose-dependent GLP-1 and GIP secretion in vitro are
prevented by pharmacological SGLT1 inhibitors [7] and
that SGLT1 knockout mice have impaired GIP and
GLP-1 release early after glucose gavage [8]. By contrast,
plasma GLP-1 levels measured later after glucose admin-
istration appeared markedly elevated in mice lacking
SGLT1, suggesting that attenuated glucose absorption
in the upper small intestine results in increased delivery
to the L-cell richer distal gut, where alternative sensing
pathways may be recruited [9]. One hypothesis is that anwww.sciencedirect.com increased distal glucose load facilitates microbial fermen-
tation and the production of short chain fatty acids, which
in turn activate L-cells via alternative signalling pathways
[10]. SGLT1 independent glucose-sensing pathways
have, however, been identified in enteroendocrine cells,
and may contribute to the delayed elevation of GLP-1
levels in SGLT1 knockout mice. L-cells and K-cells
express glucokinase and ATP sensitive potassium (KATP)
channel subunits, providing the machinery to couple
electrical activity to glucose metabolism. This pathway
seems not to be responsible for the peak incretin levels
detected early after glucose ingestion, which were unaf-
fected in humans treated with KATP channel inhibitors
[11]. Measurement of L-cell glucose concentrations
suggests that although the SGLT1-mediated Na+ flux
is large enough to drive membrane depolarisation, the
accompanying monosaccharide flux is insufficient to alter
intracellular glucose concentrations. L-cells have a highCurrent Opinion in Pharmacology 2013, 13:922–927
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facilitative glucose transporters could equilibrate cyto-
plasmic with basolateral glucose levels, and that L-cell
metabolism would predominantly be influenced by glu-
cose arriving from the plasma rather than luminal glucose
direction [7]. The interplay between plasma glucose,
metabolism and GLP-1 secretion remains, however, an
enigma. A third, and highly controversial pathway links
enteroendocrine secretion to activation of sweet taste
receptors. This pathway utilises a G protein coupled
receptor heterodimer (T1R2/T1R3) as the detector of
glucose and other sweeteners and couples through the G
protein a-gustducin. a-gustducin and T1R3 have been
detected in the gut, and in some studies were found
colocalised with GLP-1 and GIP [12–14], but several
findings suggest they may not themselves act as the L-
cell glucose sensor. Convincing arguments against an
important role of sweet taste receptors are the multiple
demonstrations that ingestion of glucose, but not artificial
sweeteners, triggers elevation of plasma incretin levels in
rodents [15] and humans [16].
Lipid sensing
Products of fat ingestion have not been reported to alter
L-cell electrical activity, but are rather thought to be
sensed by G protein coupled receptors (GPCRs). In L-
cells, several GPCRs have been implicated in lipid
signalling, such as GPR120 [17], GPR119 [18,19] and
FFAR1 (GPR40) [20]. FFAR1 and GPR120 respond to
long-chain and medium-chain fatty acids, and are
thought to be Gq-coupled, activating phospholipase C
and thereby triggering IP3 mediated Ca
2+ release and
secretion of peptides [21]. Other lipids that rise in
concentration in the intestine postprandially include 2-
monoacylglycerols, which are produced from triglycer-
ides by lipases and act as ligands for GPR119 [22], which
is expressed both in K-cells and L-cells [4,5,19]. GPR119
is preferentially Gs-coupled and ligand binding results in
activation of adenylyl cyclase, an increase in cAMP levels
and enhanced L-cell secretion [19,23]. Alternative lipid
sensing pathways underlying GLP-1 secretion, involving
uptake by fatty-acid transport protein (FATP4) [24] and
activation of atypical protein kinase C [25] have also been
described.
SCFA are produced in the colon during bacterial fermen-
tation of dietary fibre or, less usually, of non-absorbed
carbohydrate. They may provide one link between fibre
content, the gut microbiome and L-cells [26,27], acting
through two GPCRs, FFAR2 and FFAR3. FFAR2 can
couple to Gq-signalling pathway and Gi/o-signalling path-
way, whilst FFAR3 seems to lack a Gq component [28
]. A
role for FFAR2 in GLP-1 secretion was suggested by the
findings that SCFA triggered Ca2+ transients in primary
L-cells and that circulating GLP-1 levels and SCFA-
dependent GLP-1 release in vitro were impaired in mice
lacking FFAR2 [29].Current Opinion in Pharmacology 2013, 13:922–927 Protein sensing
Although protein digestion is an effective stimulus of
GLP-1 release, the optimal size of the digestion products
for triggering secretion remains uncertain. Several amino
acids have been shown to stimulate GLP-1 release in vitro
[30,31]. The effectiveness of L-Gln has been attributed to
its ability both to trigger membrane depolarisation via
electrogenic Na+-dependent amino acid uptake, and to
elevate cytoplasmic cAMP concentrations, perhaps
though activation of an unidentified Gs-coupled GPCR
[30,31]. Ingestion of L-Gln also stimulates GLP-1 release
in healthy and obese and diabetic humans [32]. GPCRs
have been linked to the sensing of other luminal amino
acids by enteroendocrine cells: GPRC6A to ornithine [33]
and the CaSR to phenylalanine [34]. The sensing of larger
protein digestion products simulated by, for example
meat hydrolysate has been linked to activation of mito-
gen-activated protein (MAP) kinases, but the receptors
involved are less clear [35,36].
Non-nutrient pathways
GLP-1 secretion is not only stimulated by nutrients, but
also by other luminal components. Enteral progesterone
has been implicated in incretin secretion through acti-
vation of plasma membrane receptors [37]. Bile acids are
also involved in the integration of metabolic signals and
have been implicated in fibroblast growth factor 15/19
secretion from the distal gut downstream of the well-
characterised nuclear hormone receptor FXR [38]. In L-
cells, however, bile acids appear to stimulate GLP-1
secretion through activation of the predominantly Gs
coupled receptor TGR5 (GPBAR) [39,40]. Recently,
administration of bile acids has been shown to have
positive effects on glucose homeostasis and plasma
GLP-1 levels in human volunteers [41,42]. Interestingly
plasma bile acid levels increase after bariatric surgery,
and bile acid stimulated GLP-1 secretion might con-
tribute to the associated improvements in metabolic
control [43].
Inhibitory pathways
In addition to stimulatory pathways enhancing incretin
secretion, enteroendocrine cells also express GPCRs
coupled to Gi proteins with inhibitory functions. K-cells
and L-cells, for example, express Gi-coupled somato-
statin receptors. Somatostatin impairs the release of
GLP-1 and GIP, and in enteroendocrine cell lines inhibits
forskolin-stimulated cAMP transients, consistent with the
recruitment of a Gi coupled signalling pathway [44,45].
Enhanced somatostatin release is a likely pathway under-
lying the observed inhibition of GLP-1 secretion in
patients treated with GLP-1 mimetics [46]. The Gi-
coupled endocannabinoid receptor Cnr1 has also been
linked to modulation of incretin hormone secretion. Cnr1
is expressed at higher levels in K-cells than L-cells and
preferentially inhibits secretion of GIP rather than GLP-1
[44].www.sciencedirect.com
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signals from multiple inputs, both from ingested nutrients
and components in the gut lumen, and also from other
enteroendocrine cells and tissues. These inputs involve
on the one hand electrogenic pathways, through co-trans-
port of Na+, and the other hand GPCRs and classical
downstream G protein coupled pathways. It is hoped that
a greater understanding of the physiological signalling
pathways employed by enteroendocrine cells in vivo
could be exploited to target the cells for the treatment
of T2DM and obesity.
Therapeutic potential and future possibilities
On the basis of the fundamental importance of incretins
for glucose homeostasis, therapies based on activating the
incretin axis have proved highly effective in treating
T2DM. Stable injectable GLP-1 mimetics and inhibitors
of dipeptidyl peptidase 4 (DPP4), which rapidly inacti-
vates circulating GLP-1, are licensed for the treatment of
T2DM and, in the case of GLP-1 mimetics, offer
additional benefits such as weight loss and cardioprotec-
tion [47,48]. Therapies based on targeting endogenous
enteroendocrine cells, however, could potentially offer
the benefits of releasing more than one peptide, thus
activating appetite suppressants as well as insulinotropic
pathways. Several candidate enteroendocrine targets, in-
cluding FFAR1, GPR119 and GPR120, are currently
under investigation. Amongst these, the FFAR1 agonist
TAK-875 targets pancreatic b-cells as well as L-cells and
exhibits favourable glycaemic effects in patients with
T2DM [49], although the relative contribution of
GLP-1 may be minor. Agonists for GPR119 showed
encouraging efficacy in animal models, but had limited
glucose lowering and incretin activity in humans, for
reasons that remain to be established [50,51]. Somewhat
surprisingly, a dual acting SGLT1/2 inhibitor has recently
been shown to cause elevation in GLP-1 and PYY levels
in rodents and human patients with type 2 diabetes [9,52],
thus mimicking the effect of SGLT1 knockout, perhaps
by feeding the gut microbiome and enhancing SCFA
production in the L-cell rich distal gut [10]. It seems
likely that the markedly elevated post-prandial GLP-1
and PYY levels that follow some forms of bariatric surgery
[53] are similarly linked to increased delivery of nutrients
to the distal gut, and have dramatic effects on appetite
and T2DM resolution [54,55,56,57,58]. Mimicking the
effects of bariatric surgery by medical interventions
would be a major therapeutic breakthrough.
Conclusion
The enteroendocrine system plays a fundamental role
in orchestrating post-prandial physiology, and is central
to the regulation of glucose homeostasis and satiety.
The success of current GLP-1-based therapies and the
dramatic effects of bariatric surgery on insulin secretion
and appetite greatly support the future development of
therapeutic strategies that exploit targets upstream ofwww.sciencedirect.com enteroendocrine secretion as novel treatments for
T2DM and obesity. Despite the notable progress made
to date in dissecting the mechanisms of stimulation-
coupled enteroendocrine secretion, there are currently
no drugs clinically approved that directly target
endogenous enteroendocrine cells. The unexpected
success of bariatric surgery in treating T2DM, however,
highlights the benefits that could be achieved through a
gut-based therapeutic approach.
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